(OPCH) Option Care Health - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68404L2016

OPCH: Infusion, Therapies, Nutrition, Medications, Nursing, Services

Option Care Health, Inc. (NASDAQ:OPCH) is a leading provider of home and alternate-site infusion services in the United States. The company specializes in delivering complex therapies in non-hospital settings, reducing healthcare costs while improving patient outcomes. Their services span a wide range of clinical needs, including anti-infective therapies, heart failure treatments, parenteral and enteral nutrition, and immunoglobulin infusions for immune deficiencies. They also address chronic inflammatory conditions like Crohn’s disease, psoriasis, and rheumatoid arthritis, as well as neurological disorders such as multiple sclerosis and muscular dystrophy. Additionally, the company offers infusion therapies for bleeding disorders, high-risk pregnancies, pain management, chemotherapy, and respiratory conditions, complemented by nursing support.

Option Care Health operates through a referral-based model, working closely with physicians, hospital discharge planners, and health organizations to ensure seamless patient transitions to home-based care. This approach aligns with the broader healthcare industry’s shift toward cost-effective, patient-centric care delivery. Headquartered in Bannockburn, Illinois, the company is well-positioned to benefit from the growing demand for outpatient infusion services.

From a financial perspective, Option Care Health has a market capitalization of approximately $5.27 billion, reflecting its scale and market presence. The company trades at a P/E ratio of 25.82, with a forward P/E of 25.45, suggesting investor confidence in its growth prospects. Its price-to-book ratio of 3.70 indicates a premium valuation relative to its book value, while the price-to-sales ratio of 1.10 highlights its revenue generation capabilities. These metrics provide insight into the company’s financial health and its position as a key player in the healthcare services sector.

Additional Sources for OPCH Stock

OPCH Stock Overview

Market Cap in USD 5,330m
Sector Healthcare
Industry Medical Care Facilities
GiC Sub-Industry Health Care Services
IPO / Inception 1996-08-15

OPCH Stock Ratings

Growth 5y 65.7%
Fundamental 46.3%
Dividend 0.0%
Rel. Strength Industry 1.8
Analysts 3.9/5
Fair Price Momentum 35.40 USD
Fair Price DCF 40.23 USD

OPCH Dividends

No Dividends Paid

OPCH Growth Ratios

Growth Correlation 3m 95.6%
Growth Correlation 12m -9.1%
Growth Correlation 5y 74.6%
CAGR 5y 29.07%
CAGR/Max DD 5y 0.75
Sharpe Ratio 12m 0.73
Alpha -4.49
Beta 0.46
Volatility 31.71%
Current Volume 2194.2k
Average Volume 20d 1884.9k
What is the price of OPCH stocks?
As of March 15, 2025, the stock is trading at USD 32.66 with a total of 2,194,208 shares traded.
Over the past week, the price has changed by -3.97%, over one month by +3.81%, over three months by +39.22% and over the past year by +2.70%.
Is Option Care Health a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Option Care Health (NASDAQ:OPCH) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 46.26 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of OPCH as of March 2025 is 35.40. This means that OPCH is currently overvalued and has a potential downside of 8.39%.
Is OPCH a buy, sell or hold?
Option Care Health has received a consensus analysts rating of 3.90. Therefor, it is recommend to buy OPCH.
  • Strong Buy: 3
  • Buy: 3
  • Hold: 4
  • Sell: 0
  • Strong Sell: 0
What are the forecast for OPCH stock price target?
According to ValueRays Forecast Model, OPCH Option Care Health will be worth about 38.3 in March 2026. The stock is currently trading at 32.66. This means that the stock has a potential upside of +17.3%.
Issuer Forecast Upside
Wallstreet Target Price 37.8 15.7%
Analysts Target Price 29.7 -9.2%
ValueRay Target Price 38.3 17.3%